Drugs / ABBV-CLS-616
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06698926 | Nov 2024 → Jan 2026 | — | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-CLS-616 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698926 ↗ |
| Route | Oral | “after oral dosing” NCT06698926 ↗ |